Roivant Sciences Ltd

Roivant Sciences Ltd. engages in the biopharmaceutical business, which engages in the development of transformative medicine. Its product portfolio includes Vtama, Batoclimab, Brepocitinib, Namilumab, and RVT-2001, which aims to treat psoriasis, atopic dermatitis, thyroid eye disease, and other illnesses. The company was founded by Vivek Ramaswamy on April 7, 2014 and is headquartered in London, the United Kingdom.

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Earnings data Q1 2025

Earnings data Q2 2025

Earnings data Q3 2025

Roivant Sciences reports strong Q1 earnings and explores new opportunities

Roivant Sciences demonstrated strong financial performance, with positive results for key programs and a substantial cash position. While facing challenges in patent litigation and DTC campaign optimization, the company has opportunities to leverage payer work, explore new therapeutic potentials, and capitalize on transaction opportunities.

ROIV reports positive trial results and potential in autoimmune diseases

ROIV's earnings call highlights positive trial results, potential in autoimmune diseases, and upcoming Phase III study results. The company acknowledges challenges in proving efficacy in lupus but is optimistic about brepocitinib's potential in various indications.

Roivant Sciences doubles revenue in Q3, VTAMA gains traction

Roivant Sciences delivered strong financial results and progress in its pipeline, particularly with the successful launch of VTAMA and enrollment in key studies.
While facing challenges in market penetration and patient behavior trends, the company's strategic focus on innovation and financial discipline positions it for future success.
By leveraging opportunities in expanding indications, advancing pipeline assets, and strategic collaborations, Roivant is poised for sustained growth and value creation.

Roivant Sciences reports robust Q4 earnings and strategic growth outlook

Roivant Sciences delivered a strong financial performance with notable achievements in clinical programs and a robust cash position, indicating stability and growth potential.
While facing challenges in patient consent for biomarker analysis and legal uncertainties, the company is strategically positioned to leverage opportunities in expanding its pipeline and exploring new markets.
With a focus on balancing operational challenges and pursuing strategic growth initiatives, Roivant Sciences remains well-positioned for future success in the biopharmaceutical industry.

Roivant Sciences excels in Q1 2024 with promising autoimmune therapies

Roivant Sciences demonstrated strong performance and promising results in Q1 2024 across multiple programs
Brepocitinib's unique mechanism positions it as a potential leader in autoimmune therapies, with significant market opportunities
Capital decisions post-Immunovant data and pricing strategy alignment present challenges for Roivant
Opportunities lie in rapid commercial launches, blockbuster potential in orphan indications, and prescription acceleration strategies

Roivant Sciences excels in Q2 with $7B cash post-sale

Roivant Sciences delivered a solid performance in Q2 2024, showcasing financial strength, positive clinical outcomes, and strategic focus on value creation. While facing challenges in margin optimization and market competition, the company is well-positioned to leverage opportunities in unmet medical needs and strategic partnerships for growth.

Roivant Sciences reports strong Q3 performance and outlines growth plans

Roivant Sciences showcased strong performance with key successes and efficient development models. The company faces challenges in certain clinical trials but remains optimistic about growth opportunities. By focusing on strategic growth and efficient execution, Roivant aims to capitalize on its promising pipeline and commercial potential.

Roivant Sciences excels in Q4, eyes blockbuster sales and strategic partnerships

Roivant Sciences is strategically positioned with a focus on maximizing pipeline opportunities, prioritizing data-driven decisions, and capitalizing on the differentiation potential of brepocitinib.

Roivant Sciences excels in Q2 with strong pipeline and financials

Roivant Sciences showcased strong financial performance, a robust late-stage pipeline, and positive clinical trial data in Q2 2025.
The company faces challenges in managing expectations, pricing strategies, and balancing capital return with R&D investments.
Opportunities for growth include upcoming data releases, strategic partnerships, and optimizing business strategies for future success.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Shares of Roivant Sciences Ltd. ROIV, +1.58% surged in the extended session Thursday following a report that Roche Holding ROG, +0.62% was close to buying an experimental drug from the biotech company.

Roivant stock rallies on report of pending drug sale: WSJ

Roche Holding AG

Roivant, started by presidential candidate Vivek Ramaswamy, could seal a deal in coming days

Roivant in Talks to Sell Stomach Drug to Roche in Deal Valued at More Than $7 Billion

Roivant Sciences' ulcerative colitis therapy, RVT-3101, shows promising results in Phase 2b trial, attracting interest from major pharmaceutical companies. The company ended the fiscal year with a cash position of approximately $1.7 billion, with losses from continuing operations reaching about $1.2 billion. RVT-3101's potential revenue depends on its market penetration and comparative efficacy against existing treatments; its unique mechanism of action could make it effective for patients unresponsive to other therapies.

Roivant Sciences' RVT-3101: Advancing Ulcerative Colitis Treatment Innovation

Roivant Sciences Ltd is attracting interest from large pharmaceutical companies for its inflammatory bowel disease drug, Bloomberg News reported on Thursday, citing people familiar with the matter.

Roivant Sciences garners interest for multi-billion bowel drug - Bloomberg

Roivant Sciences Ltd. (ROIV) witnessed a jump in share price last session on above-average trading volume.

Roivant Sciences Ltd. (ROIV) Surges 8.9%: Is This an Indication of Further Gains?

Roivant saw improved revenue and EPS in the fourth quarter. The company's lead therapy is plaque psoriasis cream Vtama.

Why Shares of Roivant Sciences Rose Wednesday

After surviving some turbulent market conditions in its first years as a public company, Roivant Sciences Ltd. ROIV, +10.77% is taking on industry behemoths as it develops new treatments for ulcerative colitis, Crohn's disease and other conditions.

After ‘transformative' year, Roivant aims to challenge bigger rivals in inflammation and immunology

Roivant Sciences Ltd. (ROIV) came out with a quarterly loss of $0.20 per share versus the Zacks Consensus Estimate of a loss of $0.41.

Roivant Sciences Ltd. (ROIV) Reports Q4 Loss, Tops Revenue Estimates

BASEL, Switzerland, and LONDON, and NEW YORK, June 28, 2023 (GLOBE NEWSWIRE) -- Roivant (Nasdaq: ROIV) today reported its financial results for the fourth quarter and fiscal year ended March 31, 2023, and provided an update on the business.

UPDATE -- Roivant Reports Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2023, and Provides Business Update

Roivant Sciences Ltd. ROIV, -1.42% said Wednesday it had a net loss of $33.6 million, or 20 cents a share, for its fiscal fourth quarter to March 31, narrower than the loss of $270.1 million, o4 39 cent a share, in the year-earlier period.

Roivant Sciences' stock up 3.7% premarket after posting narrower-than-expected loss

Roivant Reports Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2023, and Provides Business Update

Andreas Halvorsen (Trades, Portfolio), the chief investment officer of Viking Global Investors, disclosed earlier this week he reduced his stake in Roivant Sciences Ltd. ( ROIV , Financial) by 14.73%.

Andreas Halvorsen Curbs Roivant Sciences Stake

BASEL, Switzerland and LONDON and NEW YORK and BOSTON, June 26, 2023 (GLOBE NEWSWIRE) -- Roivant Sciences (Nasdaq: ROIV) today announced that it will host a live conference call and webcast at 8:00 a.m. ET on Wednesday, June 28, 2023, to report its financial results for the fourth quarter and fiscal year ended March 31, 2023, and provide business update.

Roivant to Report Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2023, and Provide Business Update on Wednesday, June 28, 2023

Roivant Sciences announced positive long-term data for its midstage ulcerative colitis drug. Investors are bidding the biopharma's shares up in response to this latest clinical update.

Why Roivant Sciences Stock Is Perking Up Today

Roivant said Thursday more than a third of ulcerative colitis patients entered remission in its study. ROIV stock hit a buy point on the news.

A First-Ever In Ulcerative Colitis Sends Roivant Stock Into A Breakout

Shares of Roivant Sciences Ltd. ROIV, -2.66% gained 14% in premarket trading Thursday after the company released new long-duration data from a study of its monoclonal antibody RVT-3101 in adults with ulcerative colitis.

Roivant Sciences shares gain after ulcerative colitis treatment shows longer-term results

BASEL, Switzerland and LONDON and NEW YORK and BOSTON, June 22, 2023 (GLOBE NEWSWIRE) -- Roivant Sciences (Nasdaq: ROIV) today announced positive results from the chronic period of the TUSCANY-2 Phase 2b study of RVT-3101, a once-monthly subcutaneously administered anti-TL1A antibody.

Roivant Reports Chronic Period Data for RVT-3101 from the TUSCANY-2 Phase 2b Study in Ulcerative Colitis, Demonstrating Improved Efficacy from the Induction to Chronic Period

Roivant Sciences exhibits a strong financial outlook, backed by its substantial cash position, strategic acquisitions, and efficient R&D expense management. The company's innovative drug pipeline includes the breakthrough product VTAMA for atopic dermatitis and plaque psoriasis and RVT-3101 for ulcerative colitis, demonstrating a commitment to addressing unmet medical needs. Roivant features other late-stage products like Batoclimab, PRV-101, AXO-Lenti-PD, and RVT-802, targeted for a range of therapeutic areas and positioned for potential future success.

Roivant Sciences: Financial Fortitude And Pipeline Advancements Demonstrate Strength

Roivant Sciences recently won approval for a topical cream, VTAMA, that looks set to achieve blockbuster (>$1bn per annum) sales. The company has several other highly promising late-stage clinical assets with blockbuster potential, and multiple data readouts upcoming.

Roivant Sciences: Coming Nicely To The Boil With Multiple Opportunities

LONG BEACH, Calif. & BASEL, Switzerland--(BUSINESS WIRE)---- $ROIV #ADORING1--Dermavant Reports Positive Topline Results from ADORING 1 Phase 3 Trial of VTAMA® Cream, 1% in Adults and Children as Young as 2 Years Old.

Dermavant Reports Positive Topline Results from ADORING 1, the Second Atopic Dermatitis Phase 3 Trial of VTAMA® (tapinarof) Cream, 1% in Adults and Children as Young as 2 Years Old

Pfizer

Last December, Pfizer formed a new company with Roivant Sciences to trial an experimental IBD medication. The therapy sports a novel mechanism of action and it could be used to treat dozens of high-value indications.

Why Did Pfizer Offload This Potential Mega-Blockbuster Drug?

Roivant has an IBD drug, RVT-3101, that has performed well in phase 2 trials. The company has a strong cash position with $1.5 billion.

Why Shares of Roivant Sciences Jumped This Week

Heron Therapeutics

Growth stocks, on balance, floundered in 2022. This sharp correction in the space has clearly created some unique buying opportunities.

These 2 Growth Stocks Might Be Incredibly Undervalued Right Now

Agenus

Inovio Pharmaceuticals

Merck's decision to pay top dollar for a late-stage asset is sparking a wave of bargain buying in biotech today. Agenus, Inovio Pharmaceuticals, and Roivant Sciences are three of the biggest beneficiaries of the industrywide trend.

These 3 Nasdaq Stocks Are on Fire Today: Here's Why

Merck

Prometheus Biosciences

Roivant Sciences shares took off on the news that Merck is acquiring Prometheus Biosciences in a $10.8 billion deal as investors placed their bets on which of the two companies could be first to bring to market their promising bowel disease drug candidate.   The acquisition adds Prometheus' monoclonal antibody treatment PRA023 being developed for ulcerative colitis (UC), Crohn's disease, and systematic sclerosis-associated interstitial lung disease to Merck's drug pipeline.

News for Roivant Sciences Ltd Stock (ROIV)